Page 96 - JCTR-11-5

Journal of Clinical and
Translational Research ROCK inhibition in chronic rejection

A D

B
E

C F

Figure 7. Effect of fingolimod and Rezurock treatment alone or in combination on fibrosis pathway-related protein expression in HMDM. (A-C) Western
blots showing the expression of ROCK1, ROCK2, and Notch1, respectively. GAPDH was used as a loading control. (D-F) Graphical representations of
three independent Western blot experiments corresponding to each protein.
Notes: *p≤0.05; **p≤0.01; ***p≤0.001.

response inhibitor, prevented macrophage infiltration cycle progression, DNA replication, adaptive immune
into allografts, reducing vessel occlusion and fibrosis. In responses, and organelle assembly. Both drugs also shared
8
addition, peritoneal macrophages treated with fingolimod commonly downregulated pathways associated with
exhibited downregulation of pathways involved in cell–cell cytokine production and chemokine signaling. 10,12
adhesion and cellular defense mechanisms. 10,14 Rezurock, In our present and previous studies, GO analysis
10
a selective ROCK2 inhibitor, was superior in inhibiting revealed that Rezurock and fingolimod alone downregulated
allograft fibrosis and suppressed pathways related to cell cell cycle- and immune-related pathways in macrophages.

Volume 11 Issue 5 (2025) 90 doi: 10.36922/JCTR025270036